Literature DB >> 20001613

Current understanding in the management of sickle cell disease.

Adlette Inati1, Lola Chabtini, Marwan Mounayar, Ali Taher.   

Abstract

Sickle cell disease (SCD), the commonest monogenetic disorder worldwide, represents a major public health burden because of its significant morbidity and mortality. Advances in molecular and cellular biology have resulted in an accumulation of knowledge on sickle cell pathophysiology and broadened our understanding of the complexity of this molecular disease with heterogeneous manifestations. Natural history studies and clinical trials have provided incremental data on clinical features, complications, and predictors of severity in SCD and, above all, have laid important recommendations for prevention and treatment of complications. Disease modifying therapies that have significantly improved survival of SCD patients have been identified over recent years. Despite increasingly successful therapies and better overall survival, patients continue to die especially with increasing age and health providers caring for SCD patients face major challenges. This article will highlight modern management of SCD and its impact on the lives of affected patients.

Entities:  

Mesh:

Year:  2009        PMID: 20001613     DOI: 10.3109/03630260903347682

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  4 in total

1.  Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.

Authors:  Wanwisa Promsote; Folami Lamoke Powell; Satyam Veean; Menaka Thounaojam; Shanu Markand; Alan Saul; Diana Gutsaeva; Manuela Bartoli; Sylvia B Smith; Vadivel Ganapathy; Pamela M Martin
Journal:  Antioxid Redox Signal       Date:  2016-08-22       Impact factor: 8.401

2.  What is behind a relapse of thrombotic thrombocytopenic purpura?

Authors:  Marco Capecchi; Andrea Artoni; Maria Domenica Cappellini; Giovanna Graziadei
Journal:  Intern Emerg Med       Date:  2017-11-02       Impact factor: 3.397

3.  A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.

Authors:  E Pizzo; A A Laverty; K J Phekoo; G AlJuburi; S A Green; D Bell; A Majeed
Journal:  J Public Health (Oxf)       Date:  2014-05-05       Impact factor: 2.341

Review 4.  Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

Authors:  Esther J van Zuuren; Zbys Fedorowicz
Journal:  Cochrane Database Syst Rev       Date:  2015-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.